Arboviruses as an unappreciated cause of non-malarial acute febrile illness in the Dschang Health District of western Cameroon

Innocent M. Ali¹, Valery P. K. Tchuenkam¹, Mia Colton², Victoria Stittleburg³, Cedar Mitchell⁴, Claudia Gaither⁴, Kyaw Thwai⁴, Daniel O. Espinoza⁵, Yerun Zhu⁵, Haaris Jamal⁵, Autum Key⁶, Jonathan J. Juliano⁴, Tume B. Christopher¹, Anne Piantadosi³,⁶, Jesse J. Waggoner²,³, Matthew H. Collins³,*

¹ Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, West Region of Cameroon, Cameroon, ² Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America, ³ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America, ⁴ Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, ⁵ Emory University, Atlanta, Georgia, United States of America, ⁶ Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America

* matthew.collins@emory.edu

Abstract

Acute febrile illness is a common problem managed by clinicians and health systems globally, particularly in the Tropics. In many regions, malaria is a leading and potentially deadly cause of fever; however, myriad alternative etiologies exist. Identifying the cause of fever allows optimal management, but this depends on many factors including thorough knowledge of circulating infections. Arboviruses such as dengue (DENV) cause fever and may be underdiagnosed in sub-Saharan Africa where malaria is a major focus. We examined cases of fever in western Cameroon that tested negative for malaria and found 13.5% (13/96) were due to DENV, with 75% (9/12) of these being DENV serotype 2 infections. Two complete DENV2 genomes were obtained and clustered closely to recent isolates from Senegal and Burkina Faso. The seroprevalence of DENV in this region was 24.8% (96/387). Neutralizing antibodies to DENV2 were detected in all (15/15) seropositive samples tested. Chikungunya (CHIKV) is an arthritogenic alphavirus that is transmitted by Aedes mosquitoes, the same principal vector as DENV. The seroprevalence for CHIKV was 15.7% (67/427); however, CHIKV did not cause a single case of fever in the 96 subjects tested. Of note, being seropositive for one arbovirus was associated with being seropositive for the other (Χ² = 16.8, p<0.001). Taken together, these data indicate that Aedes-transmitted arboviruses are endemic in western Cameroon and are likely a common but underappreciated cause of febrile illness. This work supports the need for additional study of arboviruses in sub-Saharan Africa and efforts to improve diagnostic capacity, surveillance systems, and arbovirus prevention strategies.
Author summary

Acute illness with fever is common but can be challenging for clinicians to manage, particularly in resource-limited settings. In sub-Saharan Africa, malaria is a major cause of fever, but other causes of fever are poorly documented or monitored, which impairs optimal medical care to patients and implementation of public health interventions to control leading causes of disease. Viruses transmitted by mosquitoes are a prevalent and expanding problem throughout the tropics and beyond; however, there is concern that these infections frequently go undetected in sub-Saharan Africa. We discovered a previously unrecognized outbreak of dengue virus in western Cameroon by testing remnant samples from over 400 patients that presented with fever. Our results indicate that dengue has circulated in this region for decades with little recognition. This study adds important information about causes of fever in sub-Saharan Africa and advocates for increasing investment in surveillance systems and prevention strategies for mosquito-borne viruses.

Introduction

Acute febrile illnesses (AFI) commonly prompt presentation to medical attention in sub-Saharan Africa and represent challenging clinical problems. There are numerous possible etiologies, and the availability of diagnostic testing for non-malarial causes is generally limited. [1–3] Malaria remains the predominant concern in the febrile patient, and empiric antimalarials are administered in many areas for undifferentiated fever. While missing a diagnosis of malaria could have grave consequences, overuse of antimalarials could promote resistance and confer unnecessary side effects, as well as delay optimal management of the true cause of the presenting illness. Studies of AFI in sub-Saharan Africa (SSA) have identified some patterns, but what is most notable is the heterogeneity of reported etiologies. [2] Thus, further development of public health capacity, including surveillance systems, is needed to inform the best decisions for clinical management and health resource allocation at the local level. To address gaps in epidemiologic knowledge in western Cameroon, we asked whether arbovirus (ARBV) infection was a common cause of non-malaria acute febrile illness (nmAFI).

ARBVs transmitted by the anthropophilic vector Aedes aegypti [4,5] include dengue (DENV), Zika (ZIKV) and chikungunya (CHIKV) viruses and represent a major global health problem. [6,7] DENV is estimated to cause upwards of 400 million infections each year, [8,9] with 3.6 billion people at risk of acquiring a DENV infection. [10,11] DENV was responsible for about 41,000 deaths in 2017, [12] with an economic cost estimated at 2.1 billion USD between 2000–2007 for the Americas. [13] However, the precise global distribution and burden of DENV remains highly uncertain. [14] In SSA, DENV is endemic in at least 34 countries. There is currently no report of routine DENV diagnosis and treatment in health systems in Africa despite evidence of continuous, ongoing DENV transmission in East and West Africa, [1,15,16] and more recently in central Africa. [17–19] Consequently, febrile children and adults are managed as presumptive cases of malaria or bacterial infections, which limits the attention and awareness for infections caused by DENV or other viruses. Indeed, over treatment of malaria in Africa is well documented. Up to 70% of patients in Cameroon [20] and 88% in Ghana who received an artemisinin combination were negative for malaria by rapid diagnostic test. [21] The entrenched clinical paradigm of managing undiagnosed febrile patients with antimalarials, the lack of guidelines for ARBV control programs, and the accumulating record of DENV transmission among travellers to and residents of Cameroon and other places in SSA [2,3,22–26] all point to the probability that DENV is an important public health threat.
health problem in SSA. In this study, we hypothesised that ARBV such as DENV represent an important but underappreciated etiology of febrile illness in SSA countries such as Cameroon and investigated the hospital prevalence of DENV infection in a cross-sectional acute febrile illness survey of patients suspected of having malaria infection in Dschang, West region of Cameroon.

**Methods**

**Ethics statement**

The study was reviewed and approved by the institutional review board (IRB) of the Cameroon Baptist Convention Health Board (FWA00002077), Protocol IRB2019-40. Written informed consent was administered in French or English based on participant preference, via an independent translator (who also spoke the local language Yemba) as needed. For children, informed consent was obtained from a parent or guardian.

**Study design and operations**

**Design.** The analysis presented in this article was a secondary analysis of remnant samples collected during a parent study focused on malaria. The parent study was a prospective hospital based cross-sectional survey in the three main health facilities in the Dschang Health District in the West region of Cameroon: Dschang district hospital, St Vincent Catholic Hospital and Batsinglah Catholic Hospital.

**Study population and site description.** The parent study for this project was designed to study the species and genetics of parasites causing malaria in this region of Cameroon (S1 Text). In total, 431 patients were enrolled between June 12, 2020 – September 8, 2020. Selected demographic variables are reported in Table 1, and clinical symptoms are detailed in S1 Table. The Dschang health district with its 22 health areas has a surface area of about 1060 km². It is a tropical, semi-urban environment at an elevation of 1380-1400m above sea level. The rainy season lasts mid-March–mid October.

**Recruitment of study participants and biospecimens.** Inclusion criteria of the parent study included fever (axillary temperature ≥37.5˚C or self-reported history of fever) in past 24 hours without signs and symptoms suggestive of severe malaria. Participants were excluded if they had used anti-malarial medicine in the past 14 days. Dried blood spots (DBS) were collected via finger prick. For serologic studies, plasma proteins were eluted from DBS as previously described. [23,28,29] DBS eluate was heat inactivated for 30 minutes at 56˚C and stored at 4˚C for up to 1 week or at -20˚C until use. One 6-mm hole punch of each DBS was reserved for molecular testing.

**Laboratory assays and cartography (see S1 Text for greater detail).** Samples were tested as extensively as allowed by specimen quantity and assay costs. Testing of 96 malaria-negative fever cases by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) was prioritized, followed by serologic testing of all samples with remaining material for DENV and CHIKV. Genomic sequencing could be accomplished from the same nucleic acid extraction as rRT-PCR testing.

**rRT-PCR testing.** Total nucleic acids were extracted from DBS on an EMAG instrument (bioMérieux, Durham, NC) by first placing 6mm punches into 400μL of Nuclisense lysis buffer and incubating overnight at room temperature on a tube rocker. Eluted nucleic acid (5μL) was immediately tested by multiplex rRT-PCR for ZIKV, CHIKV, and DENV, [30] and DENV-positive samples were subsequently tested in a DENV multiplex assay to determine the serotype (S1 Fig). [31,32]
DENV genome sequencing and phylogenetic analysis. Seven samples underwent unbiased metagenomic sequencing followed by DENV-specific analysis. Reads underwent metagenomic classification and DENV genome assembly. For phylogenetic analysis, all complete DENV2 genomes were downloaded from NCBI on 7/3/22 (N = 3,229), and a maximum likelihood phylogenetic tree was constructed as described in S1 Text. After Cameroon sequences were confirmed to cluster with other DENV2 sequences of the Cosmopolitan genotype from West Africa (S2 Fig), a subset of 29 West African DENV2 Cosmopolitan sequences were used for further analysis (S2 Table). Sequence GQ398264 (Indonesia, 1976) was included as an outgroup. Maximum-likelihood and time-scaled Bayesian phylogenetic analyses were performed as described in the Supplementary Methods.

Viruses and cells. DENV WHO reference strains DENV1-4 and CHIKV strain 181/clone25, [33] which is a live attenuated vaccine strain compatible with BSL-2 work, were used. DENV stocks were prepared in C6/36 Aedes albopictus mosquito cells (American Type Culture Collection (ATCC) no. CRL-1660) and CHIKV stocks in Vero Cercopithecus aethiops monkey cells (ATCC no. CCL-81).

Antigen capture IgG ELISA. Binding IgG to DENV or CHIKV was measured by antigen capture ELISA as previously described. [34,35] Virus-reactive monoclonal antibody was used to capture virus antigen. Serum IgG binding to viral antigen was detected by an alkaline phosphatase-conjugated goat anti-human IgG secondary Ab and p-nitrophenyl phosphate.
substrate. Absorbance at 405 nm (optical density, OD) was measured. The cut off for positivity was calculated for each plate as the average OD of negative control serum + three standard deviations + 0.1. [23,28,29]

Neutralization assays. Neutralization titers were determined by 96-well micro focus reduction neutralization test (microFRNT) as previously described. [23,36,37] Serial dilutions of DBS eluate were mixed with approximately 75–100 focus-forming units of virus. After 24–72 hr (depending on virus), intracellular viral protein was detected by 4G2 [38] (for DENV2) or CHK-48 [39] (for CHIKV), foci were quantitated, and neutralizing antibody titers calculated (GraphPad Prism 7).

Map creation. Data were summarized by study site (S3 Table) and were mapped to study site locations using pie charts. All maps were made using ArcGIS version 10.7.1 with Cameroon boundary shapefiles obtained from GADM.org.

Data management and statistical analysis
Clinical and sociodemographic data were collected at enrolment and were entered into the study database. Descriptive statistics were used to report prevalence of DENV cases and DENV and CHIKV seroprevalence. Associations between DENV infection outcomes and sociodemographic data were investigated by analysing cleaned data in Statistical Analysis Software (SAS). A logistic regression was performed to analyse the relationship between the parameters of interest and each of the infection outcomes. However, due to the highly dimensional data, the analysis model was prone to overfitting. Thus, a Chi-square test was conducted to compare the categorical variables to the outcome of interest. Fisher’s exact test was conducted for variables with less than 5 observations when appropriate.

Results
ARBV infection
Of 96 subjects with fever and negative malaria testing, 13 (13.5%) tested positive for DENV by ZCD assay [30] (Table 2). DENV2 was identified in 9 samples (75%), and DENV3 was identified in 4, with a single sample testing positive for both serotypes. No samples were positive for ZIKV or CHIKV RNA, and all 96 samples yielded a positive signal for the RNase P target (S4 Table). One sample could not be serotyped.

Samples with the lowest Ct values for DENV2 were sequenced. Approximately 1 million unbiased metagenomic sequencing reads were generated per sample (range 850,949 to 1,097,048, S5 Table). Complete DENV genomes were assembled from samples DSG2020_345 and DSG2020_061, confirming serotype 2. No DENV reads were detected in the other five samples (S5 Table), which can be attributed to their relatively low DENV RNA content (Cₜ values ranging from 34.95 to 42.90 in the ZCD assay), combined with our low-depth, unbiased sequencing approach; although a DENV-targeted approach likely would have yielded some DENV reads, it would be unlikely to allow full-genome sequencing and phylogenetic analysis for low-input samples such as these. Although one sample (DSG2020_346) contained GB virus C, no other potential pathogens were identified by metagenomic analysis. The two DENV2 genomes belonged to the Cosmopolitan genotype, and fell within a sub-lineage with sequences that have been circulating in West Africa for 20–35 years. [40,41] Interestingly, these sequences were distinct from and ancestral to sequences obtained from Burkina Faso, Cote d’Ivoire, and Senegal between 2016 and 2019 (Fig 1A). The Cameroon sequences, which were from samples collected in 2020, shared a common ancestor in approximately 2017 and diverged from other West African sequences in approximately 2013 (Fig 1B).
To better understand the extent of ARBV transmission in the region, we tested for IgG antibodies to DENV and CHIKV, which revealed a seroprevalence of 24.8% (96/387) for DENV and 15.7% (67/427) for CHIKV (Fig 2A–2D). The ELISA testing approach was validated by testing a small random subset of samples for neutralizing antibodies (Fig 2E and 2F). All 15 DENV IgG+ samples exhibited neutralizing antibodies to DENV2, the most prevalent DENV serotype identified among non-malarial acute fever cases tested by rRT-PCR. To assess for coherence in ARBV infection, we analyzed the proportion of samples positive for one virus

Table 2. rRT-PCR results for DBS samples positive for DENV RNA.

| Sample Number | ZCD Assay | DENV Multiplex Assay |
|---------------|-----------|----------------------|
|               | DENV     | CHIKV | ZIKV | RNase P | DENV-1 | DENV-2 | DENV-3 | DENV-4* | Final Result |
| DSG2020_061   | 19.67     | N   | N    | 22.91 | N      | 21.92 | N      | N      | DENV-2b     |
| DSG2020_345   | 22.34     | N   | N    | 24.61 | N      | 24.95 | N      | 28.40   | DENV-2b     |
| DSG2020_346   | 35.58     | N   | N    | 26.93 | N      | 38.74 | N      | 41.10   | DENV-2     |
| DSG2020_007   | 37.03     | N   | N    | 24.30 | N      | 39.24 | N      | 40.52   | DENV-2     |
| DSG2020_262   | 37.55     | N   | N    | 24.15 | N      | 38.15 | N      | 41.11   | DENV-2     |
| DSG2020_013   | 37.95     | N   | N    | 24.24 | N      | 38.46 | N      | 41.66   | DENV-2     |
| DSG2020_012   | 38.68     | N   | N    | 24.22 | N      | 40.80 | N      | 41.17   | DENV-2     |
| DSG2020_341   | 40.59     | N   | N    | 23.62 | N      | 43.09 | N      | 42.69   | DENV-2     |
| DSG2020_003   | 35.03     | N   | N    | 23.51 | N      | 36.51 | 40.13  | 39.54   | DENV-2/-3  |
| DSG2020_429   | 34.95     | N   | N    | 27.87 | N      | N      | 37.23  | N      | DENV-3     |
| DSG2020_263   | 39.96     | N   | N    | 24.98 | N      | N      | 36.88  | N      | DENV-3     |
| DSG2020_197   | 42.90     | N   | N    | 25.96 | N      | N      | 38.43  | N      | DENV-3     |
| DSG2020_075   | 41.56     | N   | N    | 26.45 | N      | N      | N      | N      | Negative   |

Abbreviations: CHIKV, chikungunya virus; DENV, dengue virus; ZIKV, Zika virus

*Known cross-reactions occur with DENV-2, results in a low-fluorescence curve that crosses the threshold in DENV-4 channel.

aWhole genome sequences obtained

https://doi.org/10.1371/journal.pntd.0010790.t002

Fig 1. Phylogenetic analysis of DENV2 Cosmopolitan genotype sequences from West Africa. A) Maximum likelihood tree. Scale bar indicates genetic distance. Nodes in the ancestral lineage of Cameroon sequences are labeled with percent bootstrap support. B) Time-scaled maximum clade credibility tree. Nodes are labeled with posterior probability for the most recent common ancestor of Cameroon sequences (red) and its most proximal ancestor with other West African sequences (gray). Text boxes indicate the median node age and 95% HPD in years prior to 2020.

https://doi.org/10.1371/journal.pntd.0010790.g001
grouping by serostatus for the other virus (Fig 2C and 2D). There was a significant relationship between DENV and CHIKV seropositivity ($\chi^2 (1, n = 383) = 16.777, p \leq 0.00005$), consistent with the hypothesis that risk for multiple *Aedes*-borne viruses would be concentrated among some individuals.
Risk factors for ARBV infection

There was no clear geographic clustering by site for DENV cases or seroprevalence (Fig 3A and 3B). A Chi-square independence test showed that there were no significant differences between the sociodemographic factors and the epidemiologic outcomes of DENV case or seropositivity ($p > 0.05$) (Table 1). Analysis of a larger sample may reveal interesting differences in seroprevalence stratified by age, but no statistically significant relationships could be detected in the sample available for this study for age and DENV seroprevalence, $\chi^2(3, N = 387) = 7.10$, $p = 0.0687$.

Discussion

In this study, we demonstrated that DENV is clearly an important cause of AFI in SSA (at least in Cameroon). However, there may be substantial local and regional heterogeneity. Our study captured an outbreak driven primarily by DENV2 during 2020. The age distribution of DENV seroprevalence is consistent with endemic or intermittent transmission of DENV for at least several decades in the region. The seroprevalence of CHIKV further indicates that local ecology is amenable to human infection by multiple viruses transmitted by *Aedes aegypti*. Our two DENV2 genomes are important contributions to the scant phylogeographic data on DENV in SSA and suggest that a distinct lineage of the Cosmopolitan genotype of DENV2 may have been circulating unrecognized in western Cameroon for several years.

Our study adds to the limited existing evidence of DENV (including serotypes 1, 2 and 3) transmission in Cameroon in several regions. [3,17,42–51] CHIKV has been less commonly reported in Cameroon, [48,52–54] with exception of a notable outbreak in 2006. [53,54] The modest seroprevalence (~15%) of CHIKV but lack of cases in the AFI cohort illustrates a few important points. It is characteristic of many ARBV to exhibit unpredictable periodic outbreaks with intervening periods of low or absent transmission. The absence of detection of an ARBV like CHIKV in a single cohort study does not exclude this virus from being an important consideration in the etiology of AFI in this region. In fact, the seroprevalence data from...
our study and the sustained circulation of CHIKV in certain regions of Africa indicate the relevance of this pathogen. The second point is that diagnostic capacity is essential to support clinical practice and public health management of the myriad causes of fever in SSA. The association of DENV and CHIKV seropositivity strongly argues that common risk factors exist for Aedes-borne ARBV in this area, and there are several reasons why a comprehensive understanding of ARBV transmission dynamics is critical. As demonstrated by our study, ARBV such as DENV are important causes of fever, but attack rates can vary broadly from season to season or between relatively small distances. For example, 17.4% of 682 non-malaria febrile cases in a large health facility in Gabon were diagnosed as DENV, [18] and in Madagascar, DENV was the most common cause of AFI in one recent study. [55] Local epidemiology determines pre-test probability of a given diagnosis, which affects clinical decision making. Moreover, epidemiologic data permit priority setting and resource allocation by public health authorities. Detecting the true prevalence and incidence of ARBV infections can advocate for enhancing diagnostic capacity. Finally, the burden of ARBV infection represents a solvable global health problem. Vaccinology continues to advance, and it is likely that safe and effective vaccines could soon be available for ARBV including DENV, CHIKV and ZIKV. [56–60] There has also been reinvigoration of control efforts targeting mosquito vectors. [61–65] Effective implementation of these requires thorough knowledge of the local transmission ecology to design, monitor and maintain the benefit of novel interventions.

Limitations of our study include the relatively low sample amount, precluding more extensive serologic testing for other ARBV. For example, we did not test for IgM, which could have increased sensitivity for capturing acute ARBV infections. A longer longitudinal study would be necessary to capture cases of other ARBV, given the typical sporadic epidemic transmission patterns of these pathogens. Also, we were unable to collect follow up data on clinical outcomes of our DENV cases. Despite this constraint, we were able to generate a robust data set and provide new insight into ARBV transmission dynamics in SSA. DBS are an innovative tool that allows convenient sampling of large numbers of people in resource limiting setting. We and others have used DBS-based serology to study the epidemiology of arboviruses or other infectious diseases in both standard ELISA as well as multiplex platforms. [23,28,29,66–72] We have recently generated data on the stability of ARBV genomic RNA on DBS for RT-PCR diagnostic testing as well as metagenomic sequencing, [73] which will expand the possibilities for clinical studies and surveillance activities.

Conclusion
In conclusion, this work highlights the need to consider DENV and other ARBV in the differential diagnosis of AFI in SSA. Our data indicate that western Cameroon is likely not hyperendemic for DENV, but sustained transmission of at least the DENV2 serotype in this region has likely been established for many years. Further study could also clarify if there is ongoing spill over from non-human mammalian hosts [48] or involvement of vector spp. other than Aedes aegypti and albopictus mosquitoes. [19,74] The methods used in this study provide an example of robust approaches to study ARBV. Optimal clinical management of febrile patients, along with efficiency and effectiveness of public health interventions such as vector control, would be strengthened were diagnostic capacity and surveillance systems improved and prioritized.

Supporting information
S1 Table. Symptoms reported among febrile patients.

(DOCX)
S2 Table. Reference sequences used for phylogenetic analysis.
(XLSX)

S3 Table. Site-specific testing data used in map creation.
(DOCX)

S4 Table. Full data set for molecular diagnostic testing by ZCD rRT-PCR assay.
(XLSX)

S5 Table. Sequencing metrics.
(XLSX)

S1 Fig. Amplification curves for positive samples from Cameroun in the DENV multiplex assay. A-B) Amplification curves for DENV-2 positive and negative samples in the DENV-2 (yellow) channel. C) Corresponding amplification curve from A shown in the DENV-4 (red) channel. Cross-reactions are readily distinguishable and serotype calls are made based on the pattern of fluorescence. Curves are color coded: pink, Cameroun samples; blue, DENV-2 control; red, DENV-4 control.
(TIF)

S2 Fig. Maximum likelihood tree of 3,225 global DENV2 sequences. Sequences from this study (dark blue, arrow) cluster with other sequences from West Africa (medium blue) within the Cosmopolitan genotype (light blue). Other sequences are color-coded by genotype, and sequences belonging to the sylvatic lineage are in black.
(TIF)

S1 Text. Supplementary Methods.
(DOCX)

Acknowledgments
We wish to acknowledge the administrative authorities of the Dschang Health District for providing the assistance with the field work.

Author Contributions
Conceptualization: Innocent M. Ali, Jonathan J. Juliano, Matthew H. Collins.

Data curation: Valery P. K. Tchuenkam, Daniel O. Espinoza, Tume B. Christopher, Jesse J. Waggoner, Matthew H. Collins.

Formal analysis: Mia Colton, Victoria Stittleburg, Cedar Mitchell, Daniel O. Espinoza, Anne Piantadosi, Jesse J. Waggoner, Matthew H. Collins.

Funding acquisition: Innocent M. Ali.

Investigation: Innocent M. Ali, Victoria Stittleburg, Claudia Gaither, Daniel O. Espinoza, Yerun Zhu, Haaris Jamal, Autum Key, Tume B. Christopher, Anne Piantadosi.

Methodology: Cedar Mitchell.

Project administration: Innocent M. Ali, Valery P. K. Tchuenkam, Kyaw Thwai, Daniel O. Espinoza, Matthew H. Collins.

Resources: Innocent M. Ali, Jonathan J. Juliano, Tume B. Christopher.

Supervision: Innocent M. Ali, Jonathan J. Juliano, Anne Piantadosi, Matthew H. Collins.
Validation: Jesse J. Waggoner.
Visualization: Cedar Mitchell, Anne Piantadosi.
Writing – original draft: Matthew H. Collins.
Writing – review & editing: Innocent M. Ali, Valery P. K. Tchuenkam, Mia Colton, Victoria Stittleburg, Cedar Mitchell, Claudia Gaither, Kyaw Thwai, Daniel O. Espinoza, Yerun Zhu, Haaris Jamal, Autumn Key, Jonathan J. Juliano, Tume B. Christopher, Anne Piantadosi, Jesse J. Waggoner.

References

1. Mwanyika GO, Mboera LEG, Rugarabamu S, Ngingo B, Sindato C, Lutwama JJ, et al. Dengue Virus Infection and Associated Risk Factors in Africa: A Systematic Review and Meta-Analysis. Viruses. 2021 Apr 1; 13(4). https://doi.org/10.3390/v13040536 PMID: 33804839
2. Maze MJ, Bassat Q, Feasey NA, Mandomando I, Musicha P, Crump JA. The epidemiology of febrile illness in sub-Saharan Africa: implications for diagnosis and management. Clin Microbiol Infect. 2018 Aug 1; 24(8):808. https://doi.org/10.1016/j.cmi.2018.02.011 PMID: 29454844
3. Tchuandom SB, Tchadjic JC, Tchouangueu TF, Biloa MZ, Atabongken EP, Fumba MIM, et al. A cross-sectional study of acute dengue infection in paediatric clinics in Cameroon. BMC Public Health. 2019 Jul 18; 19(1):958. https://doi.org/10.1186/s12889-019-7252-9 PMID: 31319834
4. Carvalho FD, Moreira LA. Why is Aedes aegypti Linnaeus so Successful as a Species? Neotrop Entomol. 2017 Jun; 46(3):243–55. 10.1007/s13744-017-0520-4 PMID: 28401481
5. Roiz D, Wilson AL, Scott TW, Fonseca DM, Jourdain F, Müller P, et al. Integrated Aedes management for the control of Aedes-borne diseases. Horstick O, editor. PLoS Negl Trop Dis. 2018 Dec; 12(12): e0006845–e0006845. http://www.ncbi.nlm.nih.gov/pubmed/30521524
6. Morens DM, Folkers GK, Fauci AS. Emerging infections: a perpetual challenge. Lancet Infect Dis. 2008 Nov; 8(11):710–9. http://www.ncbi.nlm.nih.gov/pubmed/18992407 https://doi.org/10.1016/S1473-3099(08)70256-1 PMID: 18992407
7. Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis. 2017 Mar; 17(3):e101–6. http://www.ncbi.nlm.nih.gov/pubmed/2363266 https://doi.org/10.1016/S1473-3099(16)30518-7 PMID: 28011234
8. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. N Engl J Med. 2012 Apr; 366(15):1423–32. http://www.ncbi.nlm.nih.gov/pubmed/22494122 https://doi.org/10.1056/NEJMra1110265 PMID: 22494122
9. Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019 Sep 1; 4(9):1508–15. https://doi.org/10.1038/s41564-019-0476-8 PMID: 31182801
10. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002 Jul; 33(4):330–42. https://doi.org/10.1016/S0188-4409(02)00378-6 PMID: 1234522
11. Zeng Z, Zhan J, Chen L, Chen H, Cheng S. Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017. EClinicalMedicine. 2021 Feb 1; 32. https://doi.org/10.1016/j.eclinm.2021.1001736
12. Ayukekkong JA, Oyero OG, Nnukuw SE, Mesumbe HN, Fobisong CN. Value of routine dengue diagnosis in endemic countries. World J Virol. 2017; 6(1):9. https://doi.org/10.5501/wjv.v6.i1.9 PMID: 28239567
13. Brady OJ, Gething PW, Bhattacharya JS, Brownstein JS, Hoen AG, et al. Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus. PLoS Negl Trop Dis. 2012; 6(8). https://doi.org/10.1371/journal.pntd.0001760 PMID: 22880140
14. Agboli E, Ziahouli JBZ, Badolo A, Jost H. Mosquito-Associated Viruses and Their Related Mosquitoes in West Africa. Viruses. 2021; 13(5). https://doi.org/10.3390/v13050891 PMID: 34065928
16. Joannides J, Dzodzomeryo M, Azerigyk F, Agbosou EE, Pratt D, Osei JHN, et al. Species composition and risk of transmission of some Aedes-borne arboviruses in some sites in Northern Ghana. PLoS One. 2021 Jun 1; 16(6). https://pubmed.ncbi.nlm.nih.gov/34061882/ https://doi.org/10.1371/journal.pone.0234675 PMID: 34061882

17. Demanou M, Pouillot R, Grandadam M, Boisier P, Kamgang B, Hervé JP, et al. Evidence of dengue virus transmission and factors associated with the presence of anti-dengue virus antibodies in humans in three major towns in Cameroon. PLoS Negl Trop Dis. 2014; 8(7). https://pubmed.ncbi.nlm.nih.gov/25099996/ https://doi.org/10.1371/journal.pntd.0002950 PMID: 25099996

18. Lim JK, Fernandes JF, Yoon IK, Lee JS, Mba RO, Lee KS, et al. Epidemiology of dengue fever in Gabon: Results from a health facility-based fever surveillance in Lambaréné and its surroundings. PLoS Negl Trop Dis. 2021 Feb 1; 15(2):1–15. https://pubmed.ncbi.nlm.nih.gov/33568822/ https://doi.org/10.1371/journal.pntd.0008861 PMID: 33568822

19. Kamgang B, Vazelle M, Tedjou AN, Wilson-Bahun TA, Yougang AP, Mousson L, et al. Risk of dengue in Central Africa: Vector competence studies with Aedes aegypti and Aedes albopictus (Diptera: Culicidae) populations and dengue 2 virus. PLoS Negl Trop Dis. 2019; 13(12):1–12. https://pubmed.ncbi.nlm.nih.gov/31887138/ https://doi.org/10.1371/journal.pntd.0007985 PMID: 31887138

20. Mangham LJ, Cundill B, Achonduh OA, Ambebila JN, Lele AK, Metoh TN, et al. Malaria prevalence and treatment of febrile patients at health facilities and medicine retailers in Cameroon. Trop Med Int Health. 2012 Mar; 17(3):330–42. https://pubmed.ncbi.nlm.nih.gov/22098135/ https://doi.org/10.1111/j.1365-3156.2011.02918.x PMID: 22098135

21. Ansah EK, Narh-Bana S, Affran-Bonful H, Bart-Plange C, Cundill B, Gyapong M, et al. The impact of providing rapid diagnostic malaria tests on fever management in the private retail sector in Ghana: a cluster randomized trial. BMJ. 2015 Mar 4; 350. https://pubmed.ncbi.nlm.nih.gov/25739769/ https://doi.org/10.1136/bmj.h1019 PMID: 25739769

22. Boyce RM, Collins M, Muhindo R, Nakakande R, Ciccone EJ, Grounds S, et al. Dengue in Western Uganda: a prospective cohort of children presenting with undifferentiated febrile illness. BMC Infect Dis. 2020 Dec 1; 20(1). https://pubmed.ncbi.nlm.nih.gov/33176708/ https://doi.org/10.1186/s12879-020-05658-5 PMID: 33176708

23. Willcox AC, Collins MH, Jadi R, Keeler C, Parr JB, Dieudonné D, et al. Seroepidemiology of Dengue, Zika, and Yellow Fever Viruses among Children in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2018; 99(3):756–63. http://www.ajtmh.org/ https://doi.org/10.4269/ajtmh.18-0156 PMID: 31541167

24. Simo FBN, Bigna JJ, Kenmoe S, Ndangang MS, Temfack E, Moundipa PF, et al. Dengue virus infection in people residing in Africa: a systematic review and meta-analysis of prevalence studies. Sci Rep. 2019 Dec 1; 9(1). https://pubmed.ncbi.nlm.nih.gov/31541167/ https://doi.org/10.1038/s41598-019-50135-x PMID: 31541167

25. Sharp TM, Moreira R, Soares MJ, Miguel da Costa L, Mann J, DeLorey M, et al. Underrecognition of Dengue during 2013 Epidemic in Luanda, Angola. Emerg Infect Dis. 2015 Aug; 21(8):1311–6. http://www.ncbi.nlm.nih.gov/pubmed/26196224 https://doi.org/10.3201/eid2108.150368 PMID: 26196224

26. Jaenisch T, Junghanss T, Wills B, Brady OJ, Eckerle I, Farlow A, et al. Dengue expansion in Africa—Not recognized or not happening? [Internet]. Vol. 20. Emerging Infectious Diseases. Centers for Disease Control and Prevention (CDC); 2014. /pmc/articles/PMC4193177/?report=abstract https://doi.org/10.3201/eid2010.140487 PMID: 25271370

27.Gainon EM, Harris E, LaBeaud AD. Uncovering the Burden of Dengue in Africa: Considerations on Magnitude, Misdiagnosis, and Ancestry. Viruses. 2022 Jan 25; 14(2):233. https://pubmed.ncbi.nlm.nih.gov/35215827/ https://doi.org/10.3390/v14020233 PMID: 35215827

28. Tissera H, Amarasinghe A, De Silva AD, Kariyawasam P, Corbett KS, Katzelnic L, et al. Burden of dengue infection and disease in a pediatric cohort in urban Sri Lanka. Am J Trop Med Hyg. 2014 Jul; 91(1):132–7. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4060552&tool=pmcentrez&rendertype=abstract https://doi.org/10.4269/ajtmh.13-0540 PMID: 24865684

29. Corbett KS, Katzelnic L, Tissera H, Amarasinghe A, de Silva AD, de Silva AM. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis. 2015 Feb; 211(4):590–9. http://www.ncbi.nlm.nih.gov/pubmed/25336728 https://doi.org/10.1093/infdis/iju481 PMID: 25336728

30. Waggoner J, Jersh L, Mohamed-Hadley A, Ballesteros G, Davila MJV, Tellez Y, et al. Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. Emerg Infect Dis. 2016 Jul; 22(7):1295–7. http://wwwnc.cdc.gov/eid/article/22/7/16-0326_article.htm https://doi.org/10.3201/eid2207.160326 PMID: 27184629

31. Waggoner J, Abeynayake J, Sahoo MK, Gresh L, Tellez Y, Gonzalez K, et al. Single-reaction, multiplex, real-time r-PCR for the detection, quantitation, and serotyping of dengue viruses. PLoS Negl Trop Dis. 2013; 7(4). https://pubmed.ncbi.nlm.nih.gov/23638191/
32. Waggoner JJ, Abeynayake J, Sahoo MK, Gresh L, Teilez Y, Gonzalez K, et al. Comparison of the FDA-approved CDC DENV-1-4 real-time reverse transcription-PCR with a laboratory-developed assay for dengue virus detection and serotyping. J Clin Microbiol. 2013 Oct; 51(10):3418–20. https://pubmed.ncbi.nlm.nih.gov/23903549/ https://doi.org/10.1128/JCM.01359-13 PMID: 23903549

33. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Lupton HW. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine. 1986; 4(3):157–62. https://pubmed.ncbi.nlm.nih.gov/3020820/ https://doi.org/10.1016/0264-140x(86)90034-3 PMID: 3020820

34. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WMPB, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012 May; 109(19):7439–44. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3358852&tool=pmcentrez&rendertype=abstract https://doi.org/10.1073/pnas.1200566109 PMID: 22499787

35. Collins MH, Tu HA, Gimblet-Ochieng C, Liou GJA, Jadi RS, Metz SW, et al. Human antibody response to Zika targets type-specific quaternary structure epitopes. JCI Insight. 2019 Apr; 4(8). http://www.ncbi.nlm.nih.gov/pubmed/30996133 https://doi.org/10.1172/jci.insight.124588 PMID: 30996133

36. Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, et al. Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. Emerg Infect Dis. 2017 May; 23(5):773–81. http://wwwnc.cdc.gov/eid/article/23/5/16-1630_article.htm https://doi.org/10.3201/eid2305.161630 PMID: 28418292

37. Collins MH, Zepeida O, Blette B, Jadi R, Morales M, Pérez R, et al. Serologic surveillance of maternal Zika infection in a prospective cohort in Leon, Nicaragua during the peak of the Zika epidemic. Aboelhadi SM, editor. PLoS One. 2020 Apr; 15(4):e0230692–e0230692. https://dx.plos.org/10.1371/journal.pone.0230692 PMID: 32243482

38. Henchel EA, Gentry MK, McCown JM, Brandt WE. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg. 1982 Jul; 31(4):830–6. http://www.ncbi.nlm.nih.gov/pubmed/6285749 PMID: 6285749

39. Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, et al. Broadly Neutralizing Alpha-Virus Antibodies Bind to Epitope on E2 and Inhibit Entry and Egress. Cell. 2015 Nov; 163(5):1095–107. http://linkinghub.elsevier.com/retrieve/pii/S0092867415014063 https://doi.org/10.1016/j.cell.2015.10.050 PMID: 26553503

40. Yenamandra SP, Koo C, Chiang S, Lim HSJ, Yeo ZY, Ng LC, et al. Evolution, heterogeneity and global dispersal of cosmopolitan genotype of Dengue virus type 2. Sci Reports 2021 111. 2021 Jun 29; 11 (1):1–15. https://www.nature.com/articles/s41598-021-92783-y

41. Alfsnes K, Eldholm V, Gaunt MW, de Lamballerie X, Gould EA, Pettersson JHO. Tracing and tracking the dispersal of cosmopolitan genotype of Dengue virus to Africa during the 20th century. One Heal (Amsterdam, Netherlands). 2021 Dec 1; 13. https://pubmed.ncbi.nlm.nih.gov/34746356/ https://doi.org/10.1016/j.oneh.2021.100337 PMID: 34746356

42. Monamele GC, Demanou M. First documented evidence of dengue and malaria co-infection in children attending two health centers in Yaoundé, Cameroon. Pan Afr Med J. 2018; 29. https://pubmed.ncbi.nlm.nih.gov/30100980/ https://doi.org/10.11604/pamj.2018.29.227.15316 PMID: 30100980

43. RKG von L. First confirmed dengue-1 fever cases reported from Cameroon. J Travel Med. 2002; 9(5):273–4. https://pubmed.ncbi.nlm.nih.gov/12962604/ https://doi.org/10.2310/7060.2002.24119 PMID: 12962604

44. Nemg Simo FB, Sado Youssouf FB, Evouna Nbarga A, Bigna JJ, Melong A, Ntoude A, et al. Investigation of an Outbreak of Dengue Virus Serotype 1 in a Rural Area of Kribi, South Cameroon: A Cross-Sectional Study. Intervirology. 2018 Jun 1; 61(6):265–71. https://pubmed.ncbi.nlm.nih.gov/31048588/ https://doi.org/10.1159/000499465 PMID: 31048588

45. Mouiche MMM, Ntumvi NF, Maptue VT, Tamoufe U, Albert B, Ngum Ndze V, et al. Evidence of Low-Level Dengue Virus Circulation in the South Region of Cameroon in 2018. Vector Borne Zoonotic Dis. 2020 Apr 1; 20(4):314–7. https://pubmed.ncbi.nlm.nih.gov/31934286/ https://doi.org/10.1089/verb.2019.2531 PMID: 31934286

46. Fokam EB, Levali LD, Guzman H, Amelia PA, Titanji VPK, Tesh RB, et al. Silent circulation of arboviruses in Cameroon. East Afr Med J. 2010 Jun 1; 87(6):622–8. https://pubmed.ncbi.nlm.nih.gov/23057269/ https://doi.org/10.4314/eamj.v87i6.6208 PMID: 23057269

47. Nkenfou CN, Fainguem N, Dongmo-Nguefack F, Yatchou LG, Kameni JJK, Elong EL, et al. Enhanced passive surveillance dengue infection among febrile children: Prevalence, co-infections and associated factors in Cameroon. PLoS Negl Trop Dis. 2021 Apr 1; 15(4). https://pubmed.ncbi.nlm.nih.gov/33861747/
48. Raulino R, Thaurignac G, Butel C, Villabona-Arenas CJ, Foe T, Loui S, et al. Multiplex detection of antibodies to Chikungunya, O’nyong-nyong, Zika, Dengue, West Nile and Usutu viruses in diverse non-human primate species from Cameroon and the Democratic Republic of Congo. PLoS Negl Trop Dis. 2021; 15(1):1–20. https://pubmed.ncbi.nlm.nih.gov/33476338/

49. Galani BRT, Mapouokaw DW, Simo FBN, Mohamadou H, Chuisse PDD, Njintang NY, et al. Investigation of dengue-malaria co-infection among febrile patients consulting at Ngaoundere Regional Hospital, Cameroon. J Med Virol. 2021 Jun 1; 93(6):3350–61. https://pubmed.ncbi.nlm.nih.gov/33325045/

50. Tchuandomb SB, Tchouangueu TF, Antonio-Nkondjio C, Lissom A, Djang JON, Atabong EP, et al. Seroprevalence of dengue virus among children presenting with febrile illness in some public health facilities in Cameroon. Pan Afr Med J. 2018; 31. https://pubmed.ncbi.nlm.nih.gov/31086629/ https://doi.org/10.11604/pamj.2018.31.177.16390 PMID: 31086629

51. Youssouf FBS, Neng FBS, Ngouanet SA, Mekanda FMO, Demanou M. Detection and serotyping of dengue viruses in febrile patients consulting at the New-Bell District Hospital in Douala, Cameroon. PLoS One. 2018 Oct 1; 13(10). https://pubmed.ncbi.nlm.nih.gov/30281633/ https://doi.org/10.1371/journal.pone.0204143 PMID: 30281633

52. Maurice D, Alain SMS, Christophe V, Rene N, Irene KT, Marthe IN, et al. Molecular characterization of chikungunya virus from three regions of Cameroon. Virol Sin. 2015 Dec 1; 30(6):470–3. https://pubmed.ncbi.nlm.nih.gov/26715303/ https://doi.org/10.1007/s12250-015-3663-7 PMID: 26715303

53. Demanou M, Antonio-Nkondjio C, Ngapan E, Rousset D, Paupy C, Manuguerra JC, et al. Chikungunya outbreak in a rural area of Western Cameroon in 2006: A retrospective serological and entomological survey. BMC Res Notes. 2010; 3. https://pubmed.ncbi.nlm.nih.gov/20444282/

54. Peyrefitte CN, Rousset D, Pastorino BAM, Pouillot R, Bessaud M, Tock F, et al. Chikungunya virus, Cameroon, 2006. Emerg Infect Dis. 2007; 13(5):768–71. https://doi.org/10.3201/eid1305.061500 PMID: 17553262

55. Marks F, Liu J, Soura AB, Gasmelseed N, Operario DJ, Grundy B, et al. Pathogens That Cause Acute Febrile Illness Among Children and Adolescents in Burkina Faso, Madagascar, and Sudan. Clin Infect Dis. 2021 Oct 20; 73(8):1338–45. https://pubmed.ncbi.nlm.nih.gov/33822011/ https://doi.org/10.1093/cid/ciaab289 PMID: 33822011

56. Collins MH, Metz SW. Progress and Works in Progress: Update on Flavivirus Vaccine Development. Clin Ther. 2017 Aug; 39(8):1519–36. http://www.ncbi.nlm.nih.gov/pubmed/28754189 https://doi.org/10.1002/jmv.26732 PMID: 28754189

57. Pierson TC, Graham BS. Zika Virus: Immunity and Vaccine Development. Cell. 2016 Dec; 214(suppl 5):S488–96. http://www.ncbi.nlm.nih.gov/pubmed/27920179 https://doi.org/10.1016/j.cell.2016.09.001 PMID: 27920179

58. Erasmus JH, Rossi SL, Weaver SC. Development of Vaccines for Chikungunya Fever. J Infect Dis, 2016 Dec; 214(suppl 5):S488–96. http://www.ncbi.nlm.nih.gov/pubmed/27920179 https://doi.org/10.1093/infdis/jiw271 PMID: 27920179

59. Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019 Jan; 393(10169):350–63. http://www.ncbi.nlm.nih.gov/pubmed/30696575 https://doi.org/10.1016/S0140-6736(18)32560-1 PMID: 30696575

60. Wilder-Smith A. Dengue vaccine development: status and future [Internet], Vol. 63. Bundesgesundheitsblatt—Gesundheitsforsch—Gesundheitsschutz. Springer; 2020. p. 40–4. https://pubmed.ncbi.nlm.nih.gov/31784763/

61. Utarini A, Indriani C, Ahmad RA, Tantowiyo W, Arguni E, Ansari MR, et al. Efficacy of Wolbachia-infected mosquito deployments for the Control of Dengue. N Engl J Med. 2021 Jun 10; 384(23):2177–86. https://pubmed.ncbi.nlm.nih.gov/34107180/ https://doi.org/10.1056/NEJMoa2030243 PMID: 34107180

62. Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis. James AA, editor. PLoS Negl Trop Dis. 2016 Mar; 10(3):e0004551–e0004551. http://www.ncbi.nlm.nih.gov/pubmed/26986468 https://doi.org/10.1371/journal.pntd.0004551 PMID: 26986468

63. McGraw EA O’Neill SL. Beyond insecticides: New thinking on an ancient problem. Vol. 11. Nature Reviews Microbiology. 2013. p. 181–93. https://doi.org/10.1038/nrmicro2968 PMID: 23411863

64. Reis NN, Silva AL da, Reis EPG, Silva FC e., Reis IGN. Viruses vector control proposal: genus Aedes emphasis. Braz J Infect Dis. 2017 Jul 1; 21(4):457–63. https://pubmed.ncbi.nlm.nih.gov/28577370/ https://doi.org/10.1016/j.bjid.2017.03.020 PMID: 28577370

65. Shaw WR, Catteruccia F. Vector biology meets disease control: using basic research to fight vector-borne diseases. Nat Microbiol. 2019 Jan 1; 4(1):20–34. https://pubmed.ncbi.nlm.nih.gov/30150735/ https://doi.org/10.1038/s41564-018-0214-7 PMID: 30150735
66. Montoya M, Collins M, Dejnirattisai W, Katzelnick LC, Puerta-Guardo H, Jadi R, et al. Longitudinal analysis of antibody cross-neutralization following zika virus and dengue virus infection in Asia and the Americas. J Infect Dis. 2018; 218(4). https://doi.org/10.1093/infdis/jiy164 PMID: 29618091

67. Curtis KA, Ambrose KM, Kennedy MS, Owen SM. Evaluation of Dried Blood Spots with a Multiplex Assay for Measuring Recent HIV-1 Infection. Ho W, editor. PLoS One. 2014 Sep; 9(9):e107153–e107153. http://dx.plos.org/10.1371/journal.pone.0107153 PMID: 25232736

68. Chard AN, Trinies V, Moss DM, Chang HH, Doumbia S, Lammie PJ, et al. The impact of school water, sanitation, and hygiene improvements on infectious disease using serum antibody detection. PLoS Negl Trop Dis. 2018; 12(4):e0006418–e0006418. http://www.ncbi.nlm.nih.gov/pubmed/29659574

69. Neto EC, Rubin R, Schulte J, Giugliani R. Newborn Screening for Congenital Infectious Diseases. Emerg Infect Dis. 2004 Jun; 10(6):1069–73. http://www.ncbi.nlm.nih.gov/pubmed/15207059

70. Waterboer T, Dondog B, Michael KM, Michel A, Schmitt M, Vaccarella S, et al. Dried blood spot samples for seroepidemiology of infections with human papillomaviruses, Helicobacter pylori, Hepatitis C Virus, and JC Virus. Cancer Epidemiol Biomarkers Prev. 2012 Feb; 21(2):287–93. http://www.ncbi.nlm.nih.gov/pubmed/22147363

71. Dokubo EK, Evans J, Winkelman V, Cyrus S, Tobler LH, Asher A, et al. Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. J Clin Virol. 2014 Apr; 59(4):223–7. http://www.ncbi.nlm.nih.gov/pubmed/24529844

72. Parr JB, Lodge EK, Holzmayer V, Pepin J, Frost EH, Fried MW, et al. An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots. Clin Infect Dis. 2018 Jan; 66(2):254–60. http://www.ncbi.nlm.nih.gov/pubmed/29048459

73. Cardona-Ospina Jaime; Stittleburg Victoria; Millan Natalia; Restrepo-Chica Juliana; Key Autum; Rojas-Gallardo Diana; Plantadosi Anne; Collins Matthew; Waggoner J. Sensitive and stable molecular detection of dengue, chikungunya, and Zika viruses from dried blood spots. Am J Trop Med Hyg. 2022;

74. Audrey MMP, Roland B, Borel DT, Carelle DT, Albin F, Christophe AN, et al. A mosquito survey along a transect of urbanization in Dschang, West Region of Cameroon, reveals potential risk of arbovirus spill-overs. bioRxiv. 2019 Sep 23;763755. https://www.biorxiv.org/content/10.1101/763755v1